Ji Hyun Kim @writ__e

Resistance to mutant p53 reactivation: Precision enables elegant molecular solutions, but in the evolutionary arms race between therapy and tumor, it may also become the Achilles’ heel that limits long-term efficacy #ResearchHighlight #Y220C @sigtrans_sttt nature.com/articles/s4139…

Online now: Systemic therapy, gastrectomy, cytoreductive surgery, and HIPEC versus systemic therapy alone for #gastriccancer with limited peritoneal metastases (PERISCOPE II): results of a phase 3 trial after an unplanned commissioned interim analysis thelancet.com/journals/lanon…

keyboard_arrow_left Previous keyboard_arrow_right Next

산부인과 박멸시킨 그 남자

keyboard_arrow_left Previous keyboard_arrow_right Next

김정한 Jeong Han Kim @DrJHK

a week ago

분만기관 10년 새 261곳 사라졌다…분만병의원협회 “수가·법적 안전망 없인 붕괴” medigatenews.com/news/1122956813

0 39 42 69K 6

in my view, the focus on the T-cell exhaustion program itself is misplaced. As long as there is a continuous supply of naïve T cells that recognize the same antigenic pool, why should exhaustion of earlier T-cell waves matter? 1/2 #science #immunology pnas.org/doi/10.1073/pn…

Dear all, The Asian Society of Gynecologic Oncology (ASGO) and the European Society of Gynaecological Oncology (ESGO) cordially invite you to the 4th ASGO–ESGO Joint Webinar.

Avacopan retracted nejm.org/doi/full/10.10…

💡🔦 Your must-read for Sunday, I promise it will change your perception on ADCs!! Exquisite review in @Cancer_Cell by @BarbaraPistill2 et al: Quoting from the abstract: 👇 «Emerging evidence indicates that ADC activity extends beyond target antigen expression alone, encompassing tumor-intrinsic features and tumor microenvironment-dependent processes. This challenges the view of ADCs as strictly targeted agents and supports their conceptualization as tumor-ecosystem-targeting therapies governed by multidimensional biological determinants» cell.com/cancer-cell/fu…

Our @Annals_Oncology review on ADCs is now formatted and published on the July issue! Here the link for the 50 days' free access: authors.elsevier.com/a/1nKG73I2OQqH… Great timing with my talk in Seoul for KCA annual meeting!

Raffaele Colombo @raffcolo

3 weeks ago

It was a great honor to open the Korean Cancer Association Annual Meeting with a talk on next-generation ADCs! Great discussions in the symposium on new antibodies, bispecific antibodies, and ADCs! A sincere thank you to the organizers for their incredible hospitality #KCA2026

keyboard_arrow_left Previous keyboard_arrow_right Next

0 2 13 11K 2

ADCs are often more effective than chemo. Yet, in terms of tolerability, they are often more chemo than chemo, i.e. they deliver a higher dose of toxic payload for a longer time, producing fatigue, alopecia, nausea, neutropenia, among others. Important to be honest with patients.

Harold J. Burstein, MD, PhD, FASCO @DrHBurstein

3 weeks ago

Antibody drug conjugates move forward in 1st line mTNBC though patients will find the experience similar to chemotherapy in terms of IV infusions and side effects. wsj.com/health/pharma/… via @WSJ

2 3 21 15K 4

When we see the PROC patients: 1) is the patient appropriate for wPAC (Gr2 neuropathy, long distance) 2) appropriate for Bev (GI dysfunction etc) 3) Tolerability on oral med 4) number of prior lines 5) Biomarkers

Open question from Dr. Philip Harter: Can we characterize the population inside the red box? #ESMOgyn2026 #TRUST trial

Ifosfamide shortage alert.. 😡

SHARE offers a new LGSOC Resource guide files.constantcontact.com/163702f6001/ad… full of helpful information Check it out! #gyncsm

#ASCO2026 Short-Term Fasting (STF) vs Free Diet in Advanced OC (Marchetti et al.) 🎯 Objective: Insulin reduction after 3 NACT cycles 🔬Method: Pilot RCT, N=36 HGSOC on carbo/paclitaxel NACT; STF (36h pre → 24h post each cycle) vs free diet 📊 Results: Insulin Δ: −1.12 vs +9.76 µIU/mL, p=0.01 CRS 3 at ICS: 58.8% vs 17.6%, p=0.03 mPFS: 38 vs 24 mo, p=0.045

keyboard_arrow_left Previous keyboard_arrow_right Next

Short-term fasting during neoadjuvant chemotherapy for advanced ovarian cancer is one of the more intriguing non-drug interventions presented at #ASCO2026. The study met its primary endpoint: fasting prevented the chemotherapy-associated rise in insulin levels and demonstrated a favorable metabolic shift. The headline result was a PFS signal: • mPFS 38 months with fasting vs 24 months with free diet • HR 0.26 • Log-rank p=0.045 Before we get too excited, several important limitations deserve attention: 🔹 Only ~18 patients per arm after exclusions 🔹 Trial was powered for insulin changes, not PFS 🔹 Open-label design 🔹 Borderline statistics (95% CI 0.06–1.00; Cox p=0.056) 🔹 Multiple secondary and exploratory analyses increase the risk of false-positive findings 🔹 BRCA-mutated patients were more common in the fasting arm (50% vs 33%), which could influence outcomes 🔹 Median follow-up was only 16 months despite reporting a large difference in mPFS 🔹 Immune findings were hypothesis-generating with p-values around 0.06–0.07 🔹 Analysis appears vulnerable to selection bias from withdrawals and compliance-related exclusions The most convincing finding is that short-term fasting is feasible and biologically active, affecting insulin and metabolic pathways. The least convincing finding is a 14-month absolute PFS improvement from a dietary intervention in a 36-patient study. Interesting study. But extraordinary efficacy claims require validation in a larger multicenter randomized trial before fasting enters routine ovarian cancer practice. @OncoAlert @ASCO #asco26

keyboard_arrow_left Previous keyboard_arrow_right Next

That’s quite emotional. It’s making me think of my mentor professor who’s currently undergoing treatment for stage IV KRAS G12 mutant PDAC.

Dr Rishabh Jain @DrRishabhOnco

a month ago

#ASCO26 📖 Concomitant publication in NEJM. Pancreatic cancer may have just entered the RAS era. 🧬🔥 In the phase III RASolute 302 trial, daraxonrasib nearly doubled survival vs chemotherapy in previously treated metastatic PDAC. 🚨 👥 Study population: 500 patients with

keyboard_arrow_left Previous keyboard_arrow_right Next

1 9 15 2K 4

The question isn’t PCS vs NACT, but who benefits from which TRUST gives us signals to sharpen that selection. 1. if redesigning the trial, exclud pts with pleural effusion/carcinomatosis from the PCS arm? 2. In truly resectable disease, PCS still shows a meaningful PFS advantage

GyneOnc Debate: NACT vs PCS #ASCO2026 💁🏻Exploratory analysis (TRUST) by pleural effusion/carcinomatosis: Without (n=587): PCS wins — PFS HR 0.76, p=0.0075 ✅ With (n=101): NACT wins — PFS HR 1.43

keyboard_arrow_left Previous keyboard_arrow_right Next

#asco2026 #asco

💭 My take 67% had PFI >12mo, control mPFS 9.8mo (vs 7mo assumed). ORR doubled but curves converged by 12mo → depth ≠ duration vs platinum + PARPi. •PFI 6–12mo: HR 0.68 ✅ •PFI >12mo: HR 1.11 ❌ Hard to beat platinum in truly sensitive disease?

MIROVA / AGO-OVAR 2.34 🎯 Objective: PFS 🔬 Method: Phase II RCT, N=145, FRα-high (PS2+) 📊 Results: •mPFS 9.53 vs 9.79 mo, HR 1.00 ❌ •ORR 66% vs 33% •↑ neuropathy, ocular tox 81%

keyboard_arrow_left Previous keyboard_arrow_right Next